With this patented technology pathogens are complexed with a manganese-decapeptide-phosphate (MDP) and then exposed to UV light. Advantages include a quick, easy, and reproducible process all while lowering manufacturing process costs. The MDP system has been adapted from radiation-resistant bacteria such as Deinococcus radiodurans. The front runner of this technology is ultraIPV. More information about ultraIPV can be found at https://bmi-vaccine.net


ultraIPVTM vaccine project working towards IND enabling studies. Mission is to engineer potential commercial UVC inactivation device, produce GLP/GMP-like lots for animal safety and efficacy studies, and prepare regulatory documentation for IND application. (funded by Phase IIb NIAID Research Grant)
Vaccine project working towards the finalization of a lead candidate for an Acinetobacter Baumannii species. The UVC inactivation platform was utilized on selected planktonic and biofilm cultures with MDP and tested at WRAIR in mice. [Preliminary data was funded by Phase II NIAID Research Grant]